 Oragenics, Inc. NYSE American: OGEN, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis OM, today announces the publication of the outcome of the a specific chemical synthesis of the bicyclic CD ring of an analog of the companys lantibiotic compound, Mutacin 1140. The study, titled Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization was published in the recent issue volume 25, Issue 11 of Journal of Peptide Science. 